News NICE finalises support for CSL's HAE therapy Andembry CSL Behring's Andembry can be used to prevent recurrent attacks of HAE by the NHS, following finalised guidance from reimbursement authority NICE.
News Ionis brings long-acting treatment option to HAE patients Ionis gets FDA nod for its HAE attack prophylactic treatment Dawnzera, offering less frequent dosing than its rivals.
News KalVista bags FDA approval for delayed oral HAE drug KalVista has brought the first oral, on-demand treatment for hereditary angioedema attacks to the US market.
News Neopharmed buys Euro rights to BioCryst's HAE drug Orladeyo Neopharmed Gentili buys BioCryst's hereditary angioedema drug Orladeyo in Europe, the first stage of an international expansion for the Italian firm.
News FDA green lights CSL's once-monthly HAE drug Andembry CSL has won FDA approval for Andembry, its once-monthly subcutaneous drug to prevent hereditary angioedema (HAE) attacks.
News EU approves CSL's once-monthly HAE drug Andembry The EU has approved CSL's once-monthly Andembry for hereditary angioedema, challenging therapies from Takeda and Biocryst.
Digital FH25: Jessica DaMassa on hosting, hype, and health innovatio... In a new episode of our limited Frontiers Health series of the pharmaphorum podcast, we speak with WTF Health founder and event emcee, Jessica DaMassa
Digital Sponsored Tracking studies get smarter: AI meets human intelligence Having a continuous pulse on brand health is essential for pharmaceutical companies to inform strategic decisions and establish Key Performance Indicators (KPIs) in an ever-changing market